Long-term effects of spironolactone in peritoneal dialysis patients

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 1094-1102

  Ito, Yasuhiko ^a   Mizuno, Masashi ^a   Suzuki, Yasuhiro ^a   Tamai, Hirofumi ^b   Hiramatsu, Takeyuki ^c   Ohashi, Hiroshige ^d   Ito, Isao ^e   Kasuga, Hirotake ^f   Horie, Masanobu ^g   Maruyama, Shoichi ^a   Yuzawa, Yukio ^h   Matsubara, Tatsuaki ⁱ   Matsuo, Seiichi ^a   Watanabe, M ^j   Nishimura, H ^j   Mizutani, M ^j   Kinashi, H ^j   Dambara, A ^e   Saka, Y ^e   Toda, S ^e   Kimu, S ^e   Minoshima, K ^g   Yamaha, M ^g   Takahashi, R ^f   Kimura, K ^f   Naruse, T ^k   Matsuoka, T ^l   Inaguma, D ^m   Kurata, K ^m   more..

^a NAGOYA UNIVERSITY   (Japan)

^b ANJO KOSEI HOSPITAL   (Japan)

^c Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^d GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^e Yokkaichi Municipal Hospital   (Japan)

^f Department of Nephrology Kyoritsu Hospital   (Japan)

^g Daiyukai Daiichi Hospital   (Japan)

^h FUJITA HEALTH UNIVERSITY   (Japan)

ⁱ AICHI GAKUIN UNIVERSITY   (Japan)

^j Handa Municipal Hospital   (Japan)

^k Kasugai Municipal Hospital   (Japan)

^l Ogaki Kita Clinic   (Japan)

^m TOSEI GENERAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POTASSIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GYNECOMASTIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEPHROSCLEROSIS; OPEN STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; URINE VOLUME; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HEART STROKE VOLUME; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; SPIRONOLACTONE; STROKE VOLUME;

EID: 84906557574     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013030273     Document Type: Article

References (48)

1. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4 [Suppl 1]: S79-S91, 2009
2. Krediet RT, Balafa O: Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 6: 451-460, 2010
3. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 572-586, 2011
4. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A,Malatino LS: Left ventricularmassmonitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int 65: 1492-1498, 2004
5. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, SafarME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001
6. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, Tanimoto S, Amiya E, Hara K: Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 67: 333-340, 2005
7. StewartGA,Gansevoort RT,Mark PB, Rooney E,McDonagh TA, Dargie HJ, Stuart R, Rodger C, JardineAG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 67: 217-226, 2005
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5: 2024-2031, 1995
9. Shamseddin MK, Parfrey PS: Sudden cardiac death in chronic kidney disease: Epidemiology and prevention. Nat Rev Nephrol 7: 145-154, 2011
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717, 1999
11. Pitt B, Remme W, Zannad F,Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003
12. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms.N Engl J Med 364: 11-21, 2011
13. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 108: 1831-1838, 2003
14. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S: A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 23: 507-512, 2012
15. HausmannMJ, Liel-CohenN: Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 17: 2035-2036, 2002
16. Covic A, Gusbeth-Tatomir P,Goldsmith DJ: Is it time for spironolactone therapy in dialysis patients? NephrolDial Transplant 21: 854-858, 2006
17. McGill RL, Biederman RW, Getts RT, Hazlett SM, Sharma SB, Duran J, Brandys DE, Sysak JC, Sureshkumar KK, Sandroni SE, Marcus RJ: Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol 22: 367-372, 2009
18. Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y: An overviewof regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 16: 483-521, 2012
19. Zoccali C,Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12: 1508-1515, 2001
20. Wang AY, Lam CW, Wang M, Chan IH, Lui SF, Zhang Y, Sanderson JE: Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 24: 1962-1969, 2009
21. Wang AY,Wang M,Woo J, LawMC, ChowKM, Li PK, Lui SF, Sanderson JE: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 62: 639-647, 2002
22. Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: A critical review. Am J Kidney Dis 53: 1068-1081, 2009
23. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
24. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: Effects on the cardiovascular system. Circulation 116: 85-97, 2007
25. Ritz E: Left ventricular hypertrophy in renal disease: Beyond preload and afterload. Kidney Int 75: 771-773, 2009
26. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R: Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 27: 159-163, 2007
27. Michea L, Villagrán A, Urzúa A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52: 295-300, 2008
28. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-OkdiN, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, Shapiro JI: Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 54: 1313-1320, 2009
29. Tonbul Z, Altintepe L, Sözlü C, Yeksan M, Yildiz A, Türk S: The association of peritoneal transport properties with 24-hour blood pressure levels in CAPD patients. Perit Dial Int 23: 46-52, 2003
30. Bertocchio JP, Warnock DG, Jaisser F: Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int 79: 1051-1060, 2011
31. Shavit L, Lifschitz MD, Epstein M: Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms. Kidney Int 81: 955-968, 2012
32. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20: 2641-2650, 2009
33. Nishimura H, Ito Y,MizunoM, Tanaka A,Morita Y,Maruyama S, Yuzawa Y, Matsuo S: Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol 294: F1084-F1093, 2008
34. Okazaki A, Mori Y, Nakata M, Kimura T, Sonomura K, Sakoda C, Matsuoka E, Ishida M, Yamahara H, Kishimoto N, Nakagawa H, Matsubara H: Peritoneal mesothelial cells as a target of local aldosterone action: Upregulation of connective tissue growth factor expression via serum-and glucocorticoid-inducible protein kinase 1. Kidney Blood Press Res 32: 151-160, 2009
35. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43: 1056-1064, 2004
36. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 110: 438-441, 2001
37. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl JMed 351: 543-551, 2004
38. Oreopoulos DG, Khanna R, Williams P, Vas SI: Continuous ambulatory peritoneal dialysis-1981. Nephron 30: 293-303, 1982
39. Spital A & Sterns RH: Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 6 6: 173-176, 1985
40. Szeto CC, Chow KM, Kwan BC, Leung CB, Chung KY, Law MC, Li PK: Hypokalemia in Chinese peritoneal dialysis patients: Prevalence and prognostic implication. Am J Kidney Dis 46: 128-135, 2005
41. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 4: 542-551, 2009
42. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y, Kuller LH: Less subclinical atherosclerosis in Japanese men in Japan than inWhite men in the United States in the post-World War II birth cohort. Am J Epidemiol 165: 617-624, 2007
43. Kohro T, Yamazaki T, Sato H,Ohe K,Nagai R: The impact of a change in hypertension management guidelines on diuretic use in Japan: Trends in antihypertensive drug prescriptions from 2005 to 2011. Hypertens Res 36: 559-563, 2013
44. Woo KS, Norris RM, Nicholls G: Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 75: 967-968, 1995
45. RALESInvestigators T: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78: 902-907, 1996
46. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al: Recommendations for quantitation of the left ventricle by twodimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J AmSoc Echocardiogr 2: 358-367, 1989
47. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing GroupAmerican Society of Echocardiography's Guidelines and Standards CommitteeEuropean Association of Echocardiography: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005
48. Takasaki K, Miyata M, Imamura M, Yuasa T, Kuwahara E, Kubota K, Kono M, Ueya N, Horizoe Y, Chaen H, Mizukami N, Kisanuki A, Hamasaki S, Tei C: Left ventricular dysfunction assessed by cardiac time interval analysis among different geometric patterns in untreated hypertension. Circ J 76: 1409-1414, 2012